![Jyrki Lauri Liljeroos](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jyrki Lauri Liljeroos
Directeur/Membre du Conseil chez MODULIGHT OYJ
Fortune : 616 438 $ au 31/05/2025
Profil
Jyrki Lauri Liljeroos currently works at Eye Research Foundation, Inc., as Chairman from 2017, Heart Foundation (Finland), as Chairman from 2021, Tuomi Logistiikka Oy, as Chairman from 2020, Provex Oy, as Chairman from 2008, Tampere City Mission Ry, as Chairman from 2021, Hämeenmaan Sydänpiiri Ry, as Chairman from 2005, Sydan Suomen Alue ry, as Chairman from 2005, Pirkanmaan Kansanterveys ry, as Chairman from 2024, Modulight Oyj, as Independent Director from 2024, Tampereen Yliopiston Tukisäätiö sr, as Director from 2019, StemSight Oy, as Director from 2023, and Suomen Sydänliitto Ry, Finlands Hjärtförbund rf, as Director from 2024.
Mr. Liljeroos also formerly worked at TILT Biotherapeutics Oy, as Vice Chairman, Santen Oy, as Chairman from 2016 to 2017, Hallituspartnerit ry, as Chairman from 2018 to 2021, SantenPharma AB, as Chairman from 1998 to 2016, Pirkanmaan Kansanterveys ry, as Vice Chairman from 2014 to 2023, Serres Oy, as Director from 1993 to 2022, PareeGroup Oy, as Director from 1993 to 2022, Santen SAS, as General Manager from 2000 to 2012, Santen Pharmaceutical Co., Ltd., as Principal from 2012 to 2016, Novagali Pharma SA, as Member-Supervisoty Board from 2011 to 2012, and Santen GmbH, as President from 2001 to 2013.
Mr. Liljeroos received his Masters Business Admin degree from the University of Uppsala.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MODULIGHT OYJ 1,08 % | 27/03/2025 | 460 950 ( 1,08 % ) | 616 438 $ | 31/05/2025 |
Postes actifs de Jyrki Lauri Liljeroos
| Sociétés | Poste | Début |
|---|---|---|
| MODULIGHT OYJ | Directeur/Membre du Conseil | 01/01/2017 |
Eye Research Foundation, Inc. | Président | 01/01/2017 |
Pirkanmaan Kansanterveys ry | Président | 01/01/2024 |
Suomen Sydänliitto Ry, Finlands Hjärtförbund rf
 Suomen Sydänliitto Ry, Finlands Hjärtförbund rf Miscellaneous Commercial ServicesCommercial Services Suomen Sydänliitto Ry, Finlands Hjärtförbund rf is a health and well-being company based in Helsinki, Finland. The Finnish company provides a service called sydan.fi, which is focused on heart disease treatment and prevention for those interested in the subject. | Directeur/Membre du Conseil | 01/01/2024 |
Tampereen Yliopiston Tukisäätiö sr | Directeur/Membre du Conseil | 01/01/2019 |
Sydan Suomen Alue ry | Président | 01/01/2005 |
Hämeenmaan Sydänpiiri Ry | Président | 01/01/2005 |
Tampere City Mission Ry | Président | 01/01/2021 |
Provex Oy | Président | 01/01/2008 |
| ░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Jyrki Lauri Liljeroos
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Jyrki Lauri Liljeroos
University of Uppsala | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SANTEN PHARMACEUTICAL CO., LTD. | Health Technology |
| MODULIGHT OYJ | Electronic Technology |
| Entreprise privées | 19 |
|---|---|
Hämeenmaan Sydänpiiri Ry | |
Santen Oy
 Santen Oy Pharmaceuticals: MajorHealth Technology Santen Oy engages in the development, research, manufacture and marketing of pharmaceuticals, over-the-counter products, and medical devices. It specializes in ophthalmic pharmaceuticals. The company was founded on February 28, 1997 and is headquartered in Tampere, Finland. | Health Technology |
Serres Oy
 Serres Oy Medical SpecialtiesHealth Technology Serres Oy manufactures suction systems for operating rooms and intensive care. Its products include suction bags, canisters, disposable accessories, installation hardware, solidifying agents, serial connectors, suction ejectors, and suction bag emptying devices. The company was founded in 1973 and is headquartered in Kauhajoki, Finland. | Health Technology |
TILT Biotherapeutics Oy
 TILT Biotherapeutics Oy Pharmaceuticals: MajorHealth Technology TILT Biotherapeutics Oy is a preclinical stage company working in the field of cancer immunotherapy. It develops genetically modified oncolytic viruses that enhance T-cell therapies for cancer treatment. The company was founded by Akseli Hemminki in 2013 and is headquartered in Helsinki, Finland. | Health Technology |
StemSight Oy
 StemSight Oy Miscellaneous Commercial ServicesCommercial Services StemSight Oy is a Finnish company that develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness. The company is based in Tampere, Finland. The company's team of scientists is dedicated to delivering sight-restoring cell therapies to patients. The CEO of the company is Laura Koivusalo. | Commercial Services |
Tuomi Logistiikka Oy | |
Provex Oy | |
PareeGroup Oy | |
Hallituspartnerit ry
 Hallituspartnerit ry Hallituspartnerit ry provides expertise and training to improve the working methods of the executive board in small and medium size companies. The company was founded on March 28, 2003 and is headquartered in Pirkkala, Finland. | |
Tampere City Mission Ry | |
Novagali Pharma SA
 Novagali Pharma SA Pharmaceuticals: MajorHealth Technology Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France. | Health Technology |
Santen GmbH
 Santen GmbH Pharmaceuticals: MajorHealth Technology Santen GmbH engages in the development, production, and distribution of pharmaceutical products, with a primary focus on the field of ophthalmology. It offers solutions for the treatment of allergies, age-related macular degeneration, dry eye disease, glaucoma, and infection. The company was founded in 1994 and is headquartered in Munich, Germany. | Health Technology |
SantenPharma AB
 SantenPharma AB Pharmaceuticals: MajorHealth Technology Part of Santen Pharmaceutical Co., Ltd., SantenPharma AB is a company that manufactures pharmaceutical products and hospital equipment. The company is based in Solna, Sweden. | Health Technology |
Sydan Suomen Alue ry | |
Pirkanmaan Kansanterveys ry | |
Tampereen Yliopiston Tukisäätiö sr | Miscellaneous |
Suomen Sydänliitto Ry, Finlands Hjärtförbund rf
Suomen Sydänliitto Ry, Finlands Hjärtförbund rf Miscellaneous Commercial ServicesCommercial Services Suomen Sydänliitto Ry, Finlands Hjärtförbund rf is a health and well-being company based in Helsinki, Finland. The Finnish company provides a service called sydan.fi, which is focused on heart disease treatment and prevention for those interested in the subject. | Commercial Services |
Santen SAS
 Santen SAS Pharmaceuticals: MajorHealth Technology Part of Santen Pharmaceutical Co., Ltd., Santen SAS is a French company that conducts drug discovery and clinical development in the field of ophthalmology. The company is based in Puteaux, France. The company has a comprehensive portfolio across glaucoma and dry eye, and has also expanded into the surgical and vision correction arenas. Santen aims to become a social innovator in ophthalmology and address social and economic issues related to eye health. The company was founded in 2000. Jean-Sébastien Garrigue has been the CEO of the company since 2013. | Health Technology |
Eye Research Foundation, Inc. |
